China Shineway Pharmaceutical Group Limited
CSWYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.18 | 0.24 | 0.09 |
| FCF Yield | 108.95% | 17.20% | 22.20% | 14.89% |
| EV / EBITDA | -4.13 | -3.91 | -0.05 | 0.43 |
| Quality | ||||
| ROIC | 7.79% | 10.25% | 8.81% | 6.61% |
| Gross Margin | 74.95% | 75.15% | 74.38% | 74.77% |
| Cash Conversion Ratio | 0.84 | 1.03 | 1.66 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | 85.90% | 108.52% | 15.18% | 8.15% |
| Free Cash Flow Growth | 584.71% | -24.54% | 50.73% | 14.02% |
| Safety | ||||
| Net Debt / EBITDA | -4.75 | -4.46 | -4.98 | -5.42 |
| Interest Coverage | 137.48 | 356.42 | 1,132.67 | 426.13 |
| Efficiency | ||||
| Inventory Turnover | 1.16 | 1.25 | 1.59 | 1.36 |
| Cash Conversion Cycle | 274.34 | 241.35 | -425.88 | -296.59 |